Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications note updated to state that PubMed entries are automatically filled from PubMed and may or may not pertain to the study, replacing the previous wording. The revision/version tag was updated to v3.3.2.SummaryDifference0.0%

- Check27 days agoChange DetectedA government funding status notice was removed from the page; this site-wide operational notice described potential delays and updated operating status for the NIH Clinical Center. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page content and structure appear unchanged; no additions or deletions were detected.SummaryDifference0.2%

- Check71 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference2%

- Check78 days agoChange DetectedAppended version label (v3.1.0) and removal of multiple drug-safety related sections, indicating content consolidation and reorganization rather than new substantive content.SummaryDifference0.3%

- Check92 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.